Activist Investor Caligan Partners Discloses Significant Derivative Exposure
ANIK sits 16% above its 52-week low of $7.87.
Summary
Activist investor Caligan Partners LP amended its Schedule 13D to detail cash-settled swap agreements providing economic exposure to an additional 4.3% of Anika Therapeutics' common stock, supplementing its 9.95% direct stake.
Key Events · Ownership and Investor Activity · ANIK
-
Disclosure of Derivative Agreements
Caligan Partners LP detailed cash-settled swap agreements providing economic exposure to 623,621 shares, representing 4.3% of Anika Therapeutics' common stock.
-
Significant Economic Interest
This derivative exposure is in addition to Caligan's direct ownership of 1,435,130 shares, which constitutes 9.95% of the company's common stock, bringing their total economic interest to approximately 14.25%.
-
Activist Investor Update
The amendment from Caligan Partners, an activist investor, provides greater transparency into their full financial position and potential influence following the company's recent CEO transition.
Analysis · ANIK · Industrial Applications And Services
Caligan Partners LP, a notable activist investor and significant shareholder, filed an amendment to its Schedule 13D to provide detailed disclosure regarding its economic exposure through cash-settled swap agreements. These derivatives represent an economic interest comparable to 4.3% of Anika Therapeutics' common stock, in addition to Caligan's direct ownership of 9.95%. While Caligan disclaims beneficial ownership of the shares underlying these derivatives, this filing clarifies the full extent of their financial interest and potential influence. This update is particularly relevant for investors seeking to understand the full scope of Caligan's position, especially in the context of the company's recent CEO transition announced on January 8, 2026.
At the time of this filing, ANIK was trading at $9.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $132M. The 52-week trading range was $7.87 to $18.37. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.